Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant - Quiz - MDSpire

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

  • By

  • Benjamin A. Derman

  • Jennifer Cooperrider

  • Jacalyn Rosenblatt

  • David E. Avigan

  • Murtuza Rampurwala

  • David Barnidge

  • Ajay Major

  • Theodore Karrison

  • Ken Jiang

  • Aubrianna Ramsland

  • Tadeusz Kubicki

  • Andrzej J. Jakubowiak

  • May 29, 2024

  • 0 min

Share

Original Source(s)

Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant

  • by Benjamin A. Derman, Jennifer Cooperrider, Jacalyn Rosenblatt, David E. Avigan, Murtuza Rampurwala, David Barnidge, Ajay Major, Theodore Karrison, Ken Jiang, Aubrianna Ramsland, Tadeusz Kubicki, Andrzej J. Jakubowiak

  • May 29, 2024

Related Content

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

Case Study: Non-secretory Multiple Myeloma with Eosinophilia - Diagnostic Hurdles and a Comprehensive Literature Review

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy